|Company name||Aclaris Therapeutics, Inc.|
NEW YORK, October 4, 2019 – Bragar Eagel & Squire is investigating certain officers and directors of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) following a class action complaint that was filed against Aclaris on July 30, 2019.
The complaint alleges that throughout the class period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the company’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales; (2) that, as a result, the company was reasonably likely to face regulatory scrutiny; and (3) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you are a long-term stockholder of Aclaris securites, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.